基于人群分析的新冠疫苗接种后肾小球疾病复发风险
在加拿大不列颠哥伦比亚省1105例经活检证实的稳定期肾小球疾病成人患者中,回顾性人群队列研究显示,第一剂新冠疫苗与复发风险无关(HR=0.67),第二或第三剂与复发风险升高约两倍相关(HR=2.23),但30天绝对风险增加较低(1%-5%)。
要点
- 第一剂新冠疫苗与肾小球疾病复发风险无关(HR=0.67,95%CI 0.33-1.36)。
- 第二或第三剂疫苗与复发风险升高约两倍相关(HR=2.23,95%CI 1.06-4.71)。
- 30天绝对复发风险增加在ANCA相关肾小球肾炎、微小病变、膜性肾病或FSGS为1%-2%,在IgA肾病或狼疮肾炎为3%-5%。
核心结论
- 在肾小球疾病人群队列中,第二或第三剂新冠疫苗与较高的相对复发风险但较低的绝对风险增加相关。
研究设计与样本
- 回顾性人群队列研究,使用2000-2020年 centralized 临床和病理登记库,纳入加拿大不列颠哥伦比亚省1105例经活检证实且于2020年12月14日病情稳定的成人肾小球疾病患者。
主要发现
- 随访281天期间,134例(12.1%)患者发生复发。
- 第一剂疫苗与复发风险无关(HR=0.67;95%CI 0.33-1.36)。
- 暴露于第二或第三剂疫苗与两倍复发风险相关(HR=2.23;95%CI 1.06-4.71)。
- 相对风险模式在各肾小球疾病间相似。
- 第二或第三剂疫苗相关的30天绝对复发风险增加在ANCA相关肾小球肾炎、微小病变、膜性肾病或FSGS为1%-2%,在IgA肾病或狼疮肾炎为3%-5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although case reports have described relapses of glomerular disease after COVID-19 vaccination, evidence of a true association is lacking. In this population-level analysis, we sought to determine relative and absolute risks of glomerular disease relapse after COVID-19 vaccination. METHODS: In this retrospective population-level cohort study, we used a centralized clinical and pathology registry (2000-2020) to identify 1105 adult patients in British Columbia, Canada, with biopsy-proven glomerular disease that was stable on December 14, 2020 (when COVID-19 vaccines first became available). The primary outcome was disease relapse, on the basis of changes in kidney function, proteinuria, or both. Vaccination was modeled as a 30-day time-varying exposure in extended Cox regression models, stratified on disease type. RESULTS: During 281 days of follow-up, 134 (12.1%) patients experienced a relapse. Although a first vaccine dose was not associated with relapse risk (hazard ratio [HR]=0.67; 95% confidence interval [95% CI], 0.33 to 1.36), exposure to a second or third dose was associated with a two-fold risk of relapse (HR=2.23; 95% CI, 1.06 to 4.71). The pattern of relative risk was similar across glomerular diseases. The absolute increase in 30-day relapse risk associated with a second or third vaccine dose varied from 1%-2% in ANCA-related glomerulonephritis, minimal change disease, membranous nephropathy, or FSGS to 3%-5% in IgA nephropathy or lupus nephritis. Among 24 patients experiencing a vaccine-associated relapse, 4 (17%) had a change in immunosuppression, and none required a biopsy. CONCLUSIONS: In a population-level cohort of patients with glomerular disease, a second or third dose of COVID-19 vaccine was associated with higher relative risk but low absolute increased risk of relapse.
引用
- Canney M, Atiquzzaman M, Cunningham AM, et al. A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination. J Am Soc Nephrol. 2022. PMID: 36332971. doi:10.1681/ASN.2022030258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。